The Astronomical Cost of HIV Prevention Tools

Despite significant advancements in HIV prevention tools since the launch of the PEPFAR campaign in 2003, lack of access to prevention options led to between 1.3 million and 1.7 million new HIV infections in 2023. Gilead Sciences, Inc., a leading biopharma company, faced criticism for high drug prices, such as lenacapavir, which was priced at over US$42,000 per person per year, prompting global outrage and efforts to make it more affordable in 120 countries. However, some nations, including those whose people participated in the drug’s studies, are still being left out, highlighting ongoing concerns about Big Pharma’s pricing practices and profits.

Full Article